Does Rallies show Form 4 insider transactions for CRVS?

Yes. Rallies tracks CRVS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CRVS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CRVS. It does not provide personalized investment advice.

CRVS (Corvus Pharmaceuticals, Inc.) Stock Analysis - Insider Trades

Corvus Pharmaceuticals, Inc. (CRVS) is a publicly traded Healthcare sector company. As of May 20, 2026, CRVS trades at $12.33 with a market cap of $1.03B and a P/E ratio of -64.19. CRVS moved +5.83% today. Year to date, CRVS is +79.53%; over the trailing twelve months it is +231.25%. Its 52-week range spans $2.54 to $26.95. Analyst consensus is strong buy with an average price target of $31.60. Rallies surfaces CRVS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CRVS stock inside the company?

Recent CRVS insider activity includes MILLER RICHARD A MD bought 5.00K, MILLER RICHARD A MD bought 1.93K, ORBIMED ADVISORS LLC sold 1.18M, Thompson Peter A. sold 1.18M, and Jones William Benton bought 20.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CRVS Key Metrics

Key financial metrics for CRVS
Metric	Value
Price	$12.33
Market Cap	$1.03B
P/E Ratio	-64.19
EPS	$-0.19
Dividend Yield	0.00%
52-Week High	$26.95
52-Week Low	$2.54
Volume	1.99M
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-15.28M
Gross Margin	0.00%

Recent CRVS Insider Trades

MILLER RICHARD A MD bought 5.00K (~$60.25K) on May 18, 2026.
MILLER RICHARD A MD bought 1.93K (~$23.20K) on May 18, 2026.
ORBIMED ADVISORS LLC sold 1.18M (~$4.89M) on Jun 27, 2025.
Thompson Peter A. sold 1.18M (~$4.89M) on Jun 27, 2025.
Jones William Benton bought 20.00K (~$34.62K) on May 6, 2024.

Latest CRVS News

Corvus Ends Q1 with $236.7M Cash, Advances Soquelitinib into Phase 2 and 3 Trials — May 7, 2026
Corvus Raises $201M and Reports 72% EASI Reduction in Phase I AD Trial — Jan 23, 2026
Corvus Prices 7.9M-Share Offering at $22.15 to Raise $175M — Jan 23, 2026
Corvus Soquelitinib Achieves 72% EASI Reduction, Plans 200-Patient Phase II AD Trial — Jan 23, 2026
Phase I Data Shows 72% Mean EASI Reduction and Clean Safety Profile for Soquelitinib — Jan 23, 2026

CRVS Analyst Consensus

5 analysts cover CRVS: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $31.60.

Common questions about CRVS

Who is trading CRVS stock inside the company?: Recent CRVS insider activity includes MILLER RICHARD A MD bought 5.00K, MILLER RICHARD A MD bought 1.93K, ORBIMED ADVISORS LLC sold 1.18M, Thompson Peter A. sold 1.18M, and Jones William Benton bought 20.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CRVS?: Yes. Rallies tracks CRVS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CRVS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CRVS. It does not provide personalized investment advice.